New Study Shows Sugar-Sweetened Drinks Increase Risk of Cancer Mortality

In a large study led by researchers at the American Cancer Society, men and women who drank two or more servings of sugar-sweetened beverages (SSB) per day, compared to people who never drank, had a five percent increased risk of death from an obesity-related cancer, including gastrointestinal, postmenopausal breast, endometrial and kidney cancer.

DeepGI AI – A Thai Innovation for the Precision in Colorectal Polyp Detection

Chula Engineering and Chula Medicine co-invent an innovative device for a rapid gastrointestinal cancer detection that yields accurate results hoping to foster preventive medicine in gastrointestinal malignancy and reduce the number of cancer patients.

Mayo Clinic study provides clarity on use of anticoagulants in gastrointestinal cancers

A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers. The findings were published Wednesday, June 2, in Mayo Clinic Proceedings.

Baylor Scott & White’s Glenda Tanner Vasicek Cancer Treatment Center – Temple Announces Construction of New Radiation Oncology Facility

Baylor Scott & White Health’s Glenda Tanner Vasicek Cancer Treatment Center (VCTC) – Temple announces construction of a new radiation oncology facility that will benefit Central Texas patients being treated for cancer. With new radiation treatment equipment and more room for procedures, the facility will be able to treat up to 70 patients per day.

Gut Bacteria May be One Culprit for Increase of Colorectal Cancer in Younger People

A bacteria typically linked to periodontal disease, Fusobacterium nucleatum (F. nuc), could play an important role in the rising incidence of colorectal cancer in people under the age of 45. Another type of bacteria, Moraxella osloensis, has been found in colorectal cancer tumors at a nearly four-fold higher rate in people over 75 than in those under 45 years of age, pointing out how differences in the bacteria that comprise what is known as the body’s microbiome could affect cancer outcomes to varying degrees.
These are the preliminary findings of an ongoing study that will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco from January 23-25, 2020.

Boehringer Ingelheim and MD Anderson form unique virtual research and development center to rapidly advance new cancer therapies

Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.